[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626758":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":47,"collaborators":20,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":20,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":20,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":20,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Orna Therapeutics, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single Ascending Dose","EXPERIMENTAL","Ascending single dose of ORN252 on a specified day",[13],"Biological: ORN252",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","ORN252","ORN252 is a lipid nanoparticle encapsulating a circular RNA encoding an anti-CD19 CAR protein.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Orna Clinical Trials","CONTACT","877-728-6762","ClinicalTrials@ornatx.com",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Nucleus Network","RECRUITING","Herston","Queensland","4006","Australia","AU",{"type":37,"coordinates":38},"Point",[39,40],153.01852,-27.44453,{"lat":40,"lon":39},[43],{"name":44,"role":24,"phone":45,"phoneExt":20,"email":46},"Principal Investigator","+61 (07) 3707 2720","brisbane@nucleusnetwork.com",{"type":48,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100626758","phase-1-a-study-of-orn252-in-healthy-participants-100626758",false,"NCT07439796","A Study of ORN252 in Healthy Participants","A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ORN252 in Healthy Participants","Inclusion Criteria:\n\n* Male and female participants who are healthy as determined by the Investigator based on review of medical history, physical examination, and laboratory tests\n* Participant is willing and able to comply with study visits and other protocol requirements\n* Other protocol specific inclusion criteria may apply\n\nExclusion Criteria:\n\n* Clinically significant history or presence of organ dysfunction\n* Use of any investigational product within 3 months, or 5 half-lives, whichever longer\n* Other protocol specific exclusion criteria may apply",true,"ALL","18 Years","55 Years",{"count":61,"type":62},20,"ESTIMATED","INTERVENTIONAL",[65],"PHASE1","The purpose of this study is to assess the safety and tolerability of ORN252 in healthy adult participants.",[68],"Healthy Volunteers - Male and Female","2026-04-13",{"date":71,"type":72},"2026-04-16","ACTUAL",{"date":74,"type":72},"2026-03-16",{"date":76,"type":62},"2027-03",{"name":5,"class":6},1]